SCHEMBL21244028

SCHEMBL21244028

Cc1ccc(N2CCN(c3ccccc3NS(=O)(=O)c3ccc(C)cc3)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MCOLN3 Q8TDD5 3/20 0.60
MCOLN2 Q8IZK6 1/20 0.60
MCOLN1 Q9GZU1 1/20 0.60
L3MBTL1 Q9Y468 3/20 0.59
PKM P14618 1/20 0.59
KMT2A Q03164 6/20 0.58
GAA P10253 3/20 0.58
ALDH1A1 P00352 6/20 0.58
MAPT P10636 5/20 0.58
RECQL P46063 1/20 0.58
USP2 O75604 2/20 0.56
LMNA P02545 5/20 0.56
CYP2C9 P11712 2/20 0.56
CYP2C19 P33261 2/20 0.56
POLB P06746 2/20 0.56
NOD2 Q9HC29 1/20 0.56
KEAP1 Q14145 1/20 0.52
NFE2L2 Q16236 1/20 0.52
CA2 P00918 2/20 0.52
CA9 Q16790 2/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21244029 0.94 ALDH1A1 (0.54) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL21244025 0.92 GAA (0.71) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL23043588 0.88 MCOLN3 (0.76) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL29978509 0.88 MCOLN3 (0.76) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL5558969 0.85 MCOLN3 (0.57) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL7672822 0.83 MCOLN3 (0.62) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL21244033 0.82 MCOLN3 (0.58) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL21244032 0.82 MCOLN3 (0.58) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL23355076 0.80 KMT2A (0.59) MCOLN3MCOLN2MCOLN1L3MBTL1PKM
SCHEMBL21244030 0.80 MAPT (0.55) MCOLN3MCOLN2MCOLN1L3MBTL1PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US claimed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US claimed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US disclosed
US-10851084-B2 Piperazine derivatives as TRPML modulators Lysoway Therapeutics, Inc. (US) 2020-12-01 US disclosed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US disclosed
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS CalyGene Biotechnolgy, Inc. (US) 2019-08-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10851084-B2 Piperazine derivatives as TRPML modulators TRPM5, TRPM2, TRPM4 MCOLN3 9/4885MCOLN2 8/4885MCOLN1 7/4885
US-20190248764-A1 PIPERAZINE DERIVATIVES AS TRPML MODULATORS TRPM5, TRPM2, TRPM4 MCOLN3 9/4885MCOLN2 8/4885MCOLN1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.